About
3D-PharmXchange

A company where small dedicated teams and a high level of ownership are essential to success

We treat our clients’ projects as if they are our own. From a genuine interest, we maintain a close relationship with our clients, in which we value open and honest communication, in order to provide high quality, tailored solutions. Together we achieve more. That is why we assemble the best team together with our clients to integrate all the required expertise. In order to do so, we combine in-house expertise with external KOLs. We look beyond borders and connect all relevant parties, ranging from patients to investors, from academia to pharma.

From A to Z

We provide all core expertise needed to take a drug development program from A to B or from A to Z, if required. Whether you are looking for a complete development program design or temporary replacement, we find solutions for any challenge.

Combining decades of experience in drug development has led to the fact that today 3D has a well-known reputation for combining our experience in the industry with scientific expertise and our mission is clear; to partner with you from early on to the very end.

Industry Expertise

As a well-known player in the drug development landscape, we have partnered with an abundance of companies with products ranging from small molecules to modern-day ATMPs.

Additionally, all our staff are industry seasoned professionals making us a partner that’s known for:

  • Operational efficiency
  • Familiarity with the industry’s processes
  • Internal flexibility to deliver tailored expertise

Scientific Expertise

The people at 3D-PharmXChange are all experts in their own fields. On top of this, they are all professionals who work well in teams, maximizing their unique competences and creating value proposition that sets us apart from the competition.

Without exception, they have professional and scientific expertise that allow them to:

  • Set up a feasible development plans
  • Listen critically and identify GAPs
  • Create added value in your drug development

Three Reasons

As a company, we strive to exceed our clients’ expectations and aim to offer them an optimal balance of expertise, experience, and continuous improvement.

Working with 3D-PharmXchange means working with a motivated team that is Dedicated to accelerating Drug Development.

1. Dedicated

Dedicated to our clients

We always show dedication to our work. Whether we are asked to advise a growing biotech in their strategy or act as a program lead in an established pharmaceutical company, we become part of your team, a partner. We realize that together we achieve more. And that is why we assemble the best team together with our clients to integrate and optmize all the expertise you need to bring your product to patients.

2. Drug

From Small Molecule To ATMP

Years of experience have lead to the fact that our inhouse capabilities and knowledge that stretches from classic small molecules to modern biologicals, ATMPs, and oligosense nucleotides. The common divider in our work is that we specialize in drug products and we believe it is this focus that differentiates us from the competition.

3. Development

All Throughout Development

Our way of working as consultants means joining a team at the start and sticking with it until the end. The greatest benefits can be made by collaborating strategically early on in development and by working towards a shared goal together. One team, one goal.

Our Managing Partners

The management team consists of three seasoned professionals from the Life Sciences industry with complementary strengths and skillsets that have realized a reputation for excellence in drug development today.

Ronald van der Geest

A PhD-level clinical pharmacologist and drug delivery expert. Besides being a serial entrepreneur in the life sciences sector, he currently fulfills development leader roles within several biotech companies.

François van Och

At 3D, François combines his experience in leadership and as an expert toxicologist. He takes responsibility for the company’s operations and leads client projects in toxicology, DMPK, biopharmaceutics and early clinical research.

Inez de Greef – van der Sandt

In addition to being a partner at 3D, Inez is the CEO of Treeway, a biotechnology company  developing therapies for ALS. Over the years, she has been involved in many drug development projects with a focus on clinical development. 

Did You Know?

How we were founded

On the 1st of February 2010, 3D-PharmXchange was founded in an attic room in Riel by two of the current managing partners, Inez de Greef and Ronald van der Geest.

When we opened our first office

The first office was opened in Tilburg in May 2010.

Pivot Park

3D-PharmXchange was one of the first tenants when Pivot Park (formerly Life Science Park Oss) was launched in February 2012 and 3D opened our second office.

We love swimming

21 June 2015 – As team Treeway, we participated in the 1st edition of the New Amsterdam City Swim in the Hudson River in New York City to swim 1.5 km.

Managing Partner

François van Och became a managing partner and was appointed COO of 3D-PharmXchange in November 2016. Together with Inez de Greef and Ronald van der Geest he represents the current management team of 3D-PharmXchange.

We love mountain climbing

Last few year’s we climbed the Mont Ventoux in the tour du ALS with our team the ‘Treeway climbers’ to raise money for the development of therapies to treat Amyotrophic Lateral Sclerosis.

André van de Sande

March 2019 – Andre van de Sande joins the company’s advisory board.

10 Years of 3D

February 2020 – Our 10-year anniversary! And we would like to celebrate this with our colleagues, partners, and clients but because of the current Corona crisis, we postponed the festivities to next year.

Partners

 

The management team consists of three seasoned professionals from the Life Sciences industry with complementary strengths and skillsets that have realized a reputation for excellence in drug development today.

Ronald van der Geest

A PhD-level clinical pharmacologist and drug delivery expert who is well-known for his role in leading the development of Glybera™ for uniQure, the 1st approved gene therapy product.

François van Och

At 3D, François combines his experience in leadership and as an expert toxicologist. He takes responsibility for the company’s operations and leads client projects in toxicology, DMPK, biopharmaceutics and early clinical research.

Inez de Greef – van der Sandt

In addition to being a partner at 3D, Inez is the CEO of Treeway, a biotechnology company  developing therapies for ALS. Over the years, she has been involved in many drug development projects with a focus on clinical development.